The Journal of Urology
Volume 172, Issue 3 , Pages 920-922, September 2004

ANDROGEN REPLACEMENT AFTER CURATIVE RADICAL PROSTATECTOMY FOR PROSTATE CANCER IN HYPOGONADAL MEN

From Aurora Urology, Urology Research Options, Aurora, Colorado (JMK), and Hartford Hospital, Hartford, Connecticut (RJG)

ABSTRACT 

Purpose:

We documented the experience of 2 urology practices with the use of testosterone supplementation to treat hypogonadal men who had undergone curative radical prostatectomy for localized prostate cancer. We also reviewed the literature for reports of the use of testosterone in men surgically cured of prostate cancer.

Materials and Methods:

A retrospective review of clinical records of 2 busy private urology practices was used to compile brief case histories of hypogonadal men treated with testosterone who had undergone curative radical prostatectomy for localized prostate cancer. Using MEDLINE and BIOSIS Previews (Biological Abstracts, Inc., Philadelphia, Pennsylvania), the literature was searched for articles describing the use of testosterone in men surgically cured of organ confined prostate cancer.

Results:

The case records of 7 hypogonadal men who had undergone curative radical prostatectomy were identified. All men had clinical symptoms of hypogonadism and low serum testosterone levels. Each man was treated with an androgen preparation. After variable followup periods no biochemical or clinical evidence of cancer recurrence was found in any of the group. No reports in the literature were found of a similar therapeutic approach for such patients.

Conclusions:

Based on the clinical experience with this small group of men, and indirect evidence of the safety of this approach from epidemiological and clinical data, further cautious use of testosterone in a carefully selected population seems warranted.

Key Words:  testosterone , hypogonadism , prostatic neoplasms

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 30.00 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 Accepted for publication March 12, 2004.Supported by an unrestricted grant from Solvay Pharmaceuticals, Inc., Marietta, Georgia.

PII: S0022-5347(05)61522-4

doi:10.1097/01.ju.0000136269.10161.32

The Journal of Urology
Volume 172, Issue 3 , Pages 920-922, September 2004